The level and structure of mortality in meningococcal infection in the Russian Federation


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To characterize the structure of patients with generalized meningococcal infection (GMI) in the Russian Federation and to determine the rate of death depending on a number of factors. Materials and methods. Data on GMI cases over 2016-2019 were analyzed using Reporting Form No. 1 annually transferred from the Directorates for the Constituent Entities of the Russian Federation, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, to the Reference Centerfor Monitoring Bacterial Meningitis. The investigation included 2961 patients with a definitive diagnosis of GMI. Results. The lethal index was 18.4%. Every five children under 5 years of age and every three patients older than 65 years died. Children who had not attended preschools (disorganized children) (21.1%) were statistically significantly more likely to die from GMI than organized ones (12.9%). The chance of death in rural residents (21.5%) was 1.3 times higher than that in urban ones (17.6%). The mortality ratefor meningococcemia was 29.5%, which turned out to be higher than thatfor meningococcal meningitis (9.4%). Meningococcal serogroups B, C, W, and Y were equally responsible for high mortality rates; whereas this indicator for GMI caused by serogroup A was statistically significantly lower (10.9%). Conclusion. It is advisable to consider whether the National Calendar of Preventive Vaccinations may include scheduled meningococcal vaccination in children and whether the Calendar of Vaccinations may expand the list of groups of citizens to be mandatorily vaccinated for epidemic indications in accordance with the sanitary and epidemiological rules of СП 3.1.354218 «Prevention of Meningococcal Infection». It is promising to study the molecular and biological properties of serogroup B meningococcal strains circulating in the country, which will show the extent to which Russian serogroup B meningococcal strains are covered by the existing meningococcal vaccines.

全文:

受限制的访问

作者简介

Maria Koroleva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: korolevamaria389@gmail.com
Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis Moscow, Russia

Maria Gritsay

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: maria-griz@mail.ru
Graduate Student, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis Moscow, Russia

Irina Koroleva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: irina-korol@yandex.ru
MD, Head, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis Moscow, Russia

参考

  1. Visintin C., Mugglestone M.A., Fields E.J., Jacklin P., Murphy M.S., Pollard A.J. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ 2010; 340: 3209. https://doi. org/10.1136/bmj.c3209
  2. Pollard A.J., Nadel S., Ninis N., Faust S.N., Levin M. Emergency management of meningococcal disease: eight years on. Arch. Dis. Child. 2007; 92: 283-6. https://doi.org/10.1136/adc.2006.102384
  3. Read R.C. Neisseria meningitidis and meningococcal disease: Recent discoveries and innovations. Curr. Opin. Infect. Dis. 2019. https://doi.org/10.1097/QC0.0000000000000606
  4. Beebeejaun K., Parikh S.R., Campbell H., Gray S., Borrow R., Ramsay M.E. et al. Invasive meningococcal disease: Timing and cause of death in England, 2008-2015. J. Infect. 2020;.80:.286-90. https://doi.org/10.1016/j. jinf.2019.12.008.
  5. ECfDPaC (ECDC). Invasive meningococcal disease: Annual Epidemiological Report for 2017, on ECDC 2019. https://www. ecdc. europa.eu/sites/default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf
  6. Campbell H., Borrow R., Arumugam C., Ramsay M., Ladhani S.N. Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis. J. Infect. 2019. https://doi.org/10.1016/j. jinf.2018.11.004
  7. Wang B., Santoreneos R., Giles L., Haji Ali Afzali H., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine 2019. https://doi.org/10. 1016/j.vaccine.2019.04.020.
  8. Viner R.M., Booy R., Johnson H., Edmunds W.J., Hudson L., Bedford H. et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012; (11): 774-83. https://doi.org/10.1016/ S1474-4422(12)70180-1
  9. Dastouri F., Hosseini A., Haworth E., Khandaker G., Rashid H., Booy R. Complications of Serogroup B Meningococcal Disease in Survivors: A Review. Infect. Disord - Drug Targets 2015; 14: 205-12. https://doi.org/10.2174/1871526515999150320155614
  10. Ladhani S.N., Flood J.S., Ramsay M.E., Campbell H., Gray S.J., Kaczmarski E.B. et al. Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines. Vol. 30. Elsevier; 2012. https://doi.org/10.1016/j.vaccine.2012.03.011
  11. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004. https://doi. org/10.1016/S0140-6736(04)16725-1
  12. Campbell H., Saliba V., Borrow R., Ramsay M., Ladhani S.N. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Eurosurveillance 2015. https://doi.org/10.2807/1560-7917. ES2015.20.28.21188
  13. Parikh S.R,. Campbell H., Bettinger J.A., Harrison L.H., Marshall H.S., Martinon-Torres F. et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J. Infect. 2020. https://doi. org/10.1016/j.jinf.2020.05.079
  14. Stanton M.C., Taylor-Robinson D., Harris D., Paize F., Makwana N,. Hackett S.J. et al. Meningococcal disease in children in Merseyside, england: A 31 year descriptive study. PLoS One 2011. https://doi.org/10.1371/journal.pone.0025957
  15. Darton T., Guiver M., Naylor S., Jack D.L., Kaczmarski E.B., Borrow R. et al. Severity of meningococcal disease associated with genomic bacterial load. Clin. Infect. Dis. 2009. https://doi. org/10.1086/596707
  16. Borrow R., Alarcön P., Carlos J., Caugant D.A., Christensen H., Debbag R.et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev. Vaccines 2017. https://doi.org/10.1080/ 14760584.2017. 1258308

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##